Allogeneic, Off-the-Shelf, SARS-CoV-2-Specific T Cells (ALVR109) for the Treatment of COVID-19 in High Risk Patients

By interrogating the peripheral blood of healthy convalescent donors, researchers identified immunodominant and protective T cell target antigens, and generated and characterized polyclonal VST lines with activity against multiple clinically important SARS-CoV-2 variants.